PNC-27
p53-derived anticancer research peptide
PNC-27 (p53-derived anticancer research peptide) is a longevity & bioregulators research compound. Peptide combining a p53 HDM-2-binding domain with a membrane-resident domain — researched for selectively forming pores in cancer-cell membranes while sparing normal cells.
PNC-27 quick facts
| Reported research dosing | 100-500mcg |
| Route | Subq or IV |
| Cycle length | Research |
| Frequency | Research · Research |
| Half-life | ~2-4 hrs |
| Forms | Injectable |
| Evidence level | In-vitro + animal (oncology research) |
Strictly research-stage oncology peptide with a fascinating selectivity mechanism — no human efficacy data, not a treatment. File under 'watching.'
How PNC-27 works
Peptide combining a p53 HDM-2-binding domain with a membrane-resident domain — researched for selectively forming pores in cancer-cell membranes while sparing normal cells.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get PNC-27
Buy PNC-27 at Biolongevity Labs →PNC-27 reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for PNC-27
Graded by what exists behind each claim.
Human clinical evidence
- No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
📊 Correlative data
- This is the compound in the Vault most likely to be encountered by someone who is frightened and looking for options, and the honest position needs stating plainly: there are no human trials, no dosing established in people, and no clinical evidence of benefit in any cancer.
- It is sold in the research market with claims that outrun the data by a wide margin. Choosing it over evaluated oncology care is where the real harm sits.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 How the mechanism reads
- A peptide combining a p53 fragment with a membrane-penetrating sequence. Cell work reports it binds HDM-2 in the membranes of cancer cells and forms pores, causing necrosis — while sparing normal cells, which are said to express far less membrane HDM-2.
- The selectivity claim is the entire premise and it rests on cell culture. Selectivity that holds in a dish routinely fails in a body, where distribution, protein binding and clearance all intervene.
- A pore-forming mechanism predicts its own risk: if the selectivity is imperfect in vivo, the damage is membrane lysis in whatever tissue it reaches.
Why an empty tier is not a verdict → · What community dosing logs are worth →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What PNC-27 actually does
PNC-27 is two peptides stitched end to end, and the whole molecule only makes sense once you know which half does what. The front half is residues 12–26 of human p53 — the stretch of the p53 transactivation domain that binds HDM-2, the human double minute 2 protein. The back half is the penetratin sequence, a 16-residue run taken from the Antennapedia homeodomain that inserts into lipid bilayers. Neither half is anticancer. Bolted together they are Sarafraz-Yazdi 2010.
The mechanism is not the one the name suggests. HDM-2 is famous as the ubiquitin ligase that degrades p53, and the obvious guess is that a p53 fragment blocks that interaction and restores p53. That is not what this peptide does. It does not act in the nucleus and it does not restore p53 signaling. It acts at the plasma membrane, and its target is a pool of HDM-2 that should not be there at all.
The finding the whole compound rests on. Sarafraz-Yazdi 2010 reported substantial HDM-2 in the membranes of cancer cells and not in the membranes of untransformed cells. PNC-27 binds that membrane-bound HDM-2 through its p53 segment; penetratin then does what penetratin does, and the complex forms a transmembrane pore. The cell does not undergo apoptosis. It lyses — the contents come out.
And the experiment that makes it causal rather than correlational. The same group took MCF-10-2A cells — a non-tumorigenic breast line that PNC-27 does not kill — and transfected them with full-length HDM-2 carrying a membrane localization signal. The transfected cells became susceptible. That is the argument: put the target in the membrane of a normal cell and the normal cell dies too, which says the selectivity is not "cancer" in any general sense. It is membrane HDM-2 density, and nothing else Sarafraz-Yazdi 2010.
The structural half arrived later. Sarafraz-Yazdi 2022 reports that PNC-27 adopts a p53-peptide-like conformation when bound to HDM-2, and that pore formation is selective for the membranes that carry it. Pincus 2024 gives the mechanism its own name — poptosis, peptide-induced transmembrane pore formation — explicitly to separate it from apoptosis, because the two have different kinetics, different morphology and completely different consequences for the tissue around the dying cell.
A second target site was added in 2024, and it matters. Krzesaj 2024 reports PNC-27 also interacting with mitochondrial membranes and causing mitochondrial disruption. Mitochondria are in every cell. A second mechanism that does not depend on membrane HDM-2 is, by construction, a mechanism with no selectivity argument attached to it — and that is the most important sentence on this page.
Cell, rodent, human — and where it stops
Step one, in cell culture, repeatedly and consistently. Leukemia lines Davitt 2014, epithelial ovarian cancer lines Thadi 2020, pancreatic and breast lines in the earlier work. The readout in Thadi 2020 is the informative one: killing depended on high HDM-2 protein expression in the membranes of those lines. Same result in the leukemia line — necrosis, dependent on membrane HDM-2 Davitt 2014. Across a decade the cell-culture story has stayed internally consistent, which is more than can be said for most compounds in this Vault.
Step two, in mice. Xenograft work, mostly subcutaneous human tumors in immunodeficient animals, with tumor volume as the endpoint. Reviewed alongside the mechanism in Pincus 2024.
Step three, in humans: nothing. Zero. No phase 1. No dose-escalation. No published case series with an imaging endpoint. There is no maximum tolerated dose for this peptide in a person, because no one has ever run the study that would produce one. That is not a gap in the evidence; it is the absence of the evidence base entirely, and it is the reason every number on the card at the top of this page is an extrapolation from a vial label rather than from a trial.
The obstacles, named one at a time.
(1) A xenograft is not a patient. Immunodeficient mice have no functioning immune system, so a lytic agent that spills tumor contents into tissue provokes no inflammatory response worth measuring. In a person with an intact immune system, necrotic lysis of a large mass is an inflammatory event, and nothing in the preclinical record models that.
(2) Nobody can measure the target in a patient. The selectivity argument is entirely about how much HDM-2 sits in the plasma membrane Sarafraz-Yazdi 2010. There is no clinical assay for that. A person cannot find out whether their tumor is the kind the mechanism predicts a response in, which means the mechanism cannot be used to select who might benefit — the one thing a mechanism is for.
(3) The mitochondrial arm has no selectivity story. Krzesaj 2024 shows disruption of mitochondrial membranes. Cardiac muscle and renal tubular epithelium are the most mitochondria-dense tissues in the body and neither has been examined.
(4) Pore-forming peptides are dose-limited by red cells. Membranolytic peptides characteristically show hemolysis as the first systemic toxicity. Whether PNC-27 does at achievable exposures has not been published.
What would have to be true, and how you would know it was not
This is a preclinical research peptide, not a cancer treatment, and nothing here is medical advice. Anyone with a diagnosed malignancy needs an oncologist; the point of writing the pharmacology out is that people are going to encounter this compound anyway and deserve to know what the mechanism actually predicts. Two of these three predictions are about harm, because that is where the mechanism points.
1. A lytic agent predicts lysis chemistry, and uric acid is the cheapest way to see it. Poptosis is necrotic, not apoptotic Pincus 2024: cells rupture and dump purines, potassium and phosphate into the extracellular space. If PNC-27 were killing a meaningful mass of cells in a person, the prediction is a rising uric acid and a shifting CMP — the same chemistry signature oncology watches for after effective cytotoxic therapy. If nothing moves, the honest reading is that nothing is being lysed. That makes this the rare marker pair that is a falsification test and a safety test at the same time.
2. A pore-forming peptide predicts red cells as the first casualty. Penetratin-based membranolysis does not read a cell's identity before inserting. A CBC with attention to hemoglobin and reticulocyte count is the direct test, and a falling hemoglobin with a rising reticulocyte count would indicate the selectivity argument is not holding at whatever exposure was achieved.
3. If the compound is doing nothing, the tumor markers say so first. Where a marker is informative for the specific disease — CA-125, CEA, PSA, CA 19-9 — a trend that does not change is a real answer, and a faster answer than imaging. This prediction is here because it is the one that cuts against the product: the mechanism gives no reason to expect systemic tumor control from a peptide with a few hours in plasma, and the marker trend is how a person would find that out.
What nobody has tested yet
Four experiments nobody has run. All four are cheap by oncology standards and none of them requires dosing a person.
Nobody has published the hemolysis threshold. For a membranolytic peptide this is the first assay in the standard toxicology package — incubate with washed human erythrocytes, measure free hemoglobin across a concentration range, report the concentration at 10% lysis and compare it with the concentration that kills tumor cells. That ratio is the therapeutic index, it takes an afternoon, and it is not in the literature.
Nobody has measured membrane HDM-2 in fresh human tumor tissue. Every selectivity claim traces back to cell lines Sarafraz-Yazdi 2010 Thadi 2020. Surface biotinylation or membrane-fraction immunoblotting on surgical specimens from several tumor types would establish whether the target exists at useful density in real tumors, and would create the patient-selection assay the compound currently has no way to build.
Nobody has looked at cardiac or renal mitochondria. Since Krzesaj 2024 added a mitochondrial mechanism, the obvious follow-up is isolated cardiomyocyte and proximal tubule preparations with oxygen consumption as the readout. Until that exists, the mitochondrial finding is an unquantified risk rather than a characterized one.
Nobody has tested the null hypothesis that the p53 half is doing nothing. The clean experiment is a scrambled p53 segment fused to the same penetratin sequence, run side by side. If the scrambled version kills equally, PNC-27 is a cell-penetrating membranolytic peptide with a p53-shaped decoration, and the entire HDM-2 selectivity story is decoration too. That control would be the most informative single experiment anyone could do on this molecule.
PNC-27 — its own safety story, not its class's
The class safety block above is written for repair peptides. Almost none of it applies here, and the parts that do apply run backwards.
This compound is designed to kill cells by rupturing membranes. That is not a side effect to be minimized; it is the intended action Pincus 2024. Every safety question therefore reduces to one question — how well does the targeting hold at the concentrations reached in a person — and that question has never been asked in a human.
The selectivity is conditional, and the condition is unmeasurable. Killing tracks membrane HDM-2 density Sarafraz-Yazdi 2010 Thadi 2020, and normal cells forced to display membrane HDM-2 die like tumor cells. There is no clinical test for membrane HDM-2. So a person using this has no way to know whether they are in the population the mechanism protects.
The mitochondrial finding removes the main safety argument. Krzesaj 2024 reports interaction with mitochondrial membranes and consequent mitochondrial disruption. Mitochondrial membranes are not HDM-2-dependent and are present in every cell. Whatever protection the membrane-HDM-2 argument provides does not extend to this second mechanism, and nobody has bounded it.
The risk that has nothing to do with the peptide. The largest documented harm associated with unproven cancer compounds is delay — time spent on something unvalidated while a treatable disease progresses. That is a statement about decisions, not chemistry, and it belongs on this page more than any laboratory number does.
What would change this page. A published phase 1 with a dose-limiting toxicity and a maximum tolerated dose. That single document would replace most of what is written above, and until it exists everything here about human exposure is inference from cell culture and mice.
Sources read for this page
- Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proceedings of the National Academy of Sciences 2010 · PMID 20080680
- Sarafraz-Yazdi E, et al. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines 2022 · PMID 35625682
- Krzesaj P, et al. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption. Annals of Clinical and Laboratory Science 2024 · PMID 38802154
- Pincus MR, et al. Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells. Biomedicines 2024 · PMID 38927351
- Thadi A, et al. Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes. Annals of Clinical and Laboratory Science 2020 · PMID 33067207
- Davitt K, et al. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Annals of Clinical and Laboratory Science 2014 · PMID 25117093
PNC-27 — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Two domains fused together: a fragment of the p53 transactivation domain that binds HDM-2, and a membrane-residency segment that inserts into lipid. The proposed action is not signaling, it is physical — the peptide binds HDM-2 sitting in the plasma membrane of a cancer cell and forms a transmembrane pore, and the cell ruptures. The selectivity claim rests entirely on membrane-bound HDM-2 being present on cancer cells and absent from normal ones.
- A pore-forming peptide whose selectivity fails is a cytolytic agent. Hemolysis and non-selective membrane damage are the obvious predicted harms, and nobody has measured either in a person.
- The other prediction is what happens if it works. Killing tumor cells quickly releases their contents — tumor lysis, with the potassium, phosphate, urate and kidney consequences that go with it. That is a prediction about the mechanism succeeding, not failing, and it is the one people never plan for.
What has actually been reported
- Nothing in humans. The published work is cell culture and mouse xenograft, accumulated over about two decades by a small group. There is no clinical trial, no human pharmacokinetics and no human safety data.
- The harm attached to this compound that has actually materialized is not pharmacological. It is sold to people who have cancer, and a peptide with no clinical evidence taken instead of — or alongside — real oncology treatment is the risk on this card that does not depend on the pharmacology working or failing.
How to reduce the risk
Same mechanism as the prediction.
- If there is a cancer diagnosis anywhere in the picture, the mitigation is that the oncologist knows. Not because a doctor's permission makes a research peptide safe, but because the decision that actually changes outcomes is what it is being taken instead of.
- Baseline bloods before anything, so that a change is detectable at all.
- Treat the vial contents as unverified, because they are.
What it does to your bloodwork
A fact about the assay.
- No marker tracks the compound itself.
- The tests that would show either predicted problem are ordinary ones: full blood count for hemolysis and cytopenias, electrolytes with potassium, phosphate, calcium and urate, LDH, and kidney function. Cell lysis of the wrong cells and cell lysis of the right ones too fast look similar on that panel, which is a reason to have a baseline rather than a reason not to test.
What it overlaps with
- No interaction data exists, and none is invented here. The overlap that matters is with oncology treatment, and that belongs in a conversation with the treating team rather than on a card.
Don't run this if
- Anyone using it in place of cancer treatment. That is the entry on this card that is not about a receptor, and it is the one that matters.
- Pregnancy and breastfeeding.
- Any hemolytic condition, bleeding disorder or reduced kidney function — those are precisely where the two predicted failure modes land.
The honest unknown
- Whether the selectivity seen in a dish survives in a body, at any exposure a person could achieve. That is the entire question and it has never been asked in a human.
- Basic pharmacology — distribution, half-life, immunogenicity, what a repeated course does — none of it is characterized. And, as with any research-only peptide, what is in the vial is unverified.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Food is not a factor — pick a time you will keep
Nothing you eat touches a subcutaneous injection, so there is no meal to plan around. What does matter is a fixed slot: the commonest reason an injectable protocol underperforms is missed doses, not mistimed ones.
With a short half-life, dose it near the effect you want rather than at a fixed hour.
From half-life and route, not a dosing trial.
PNC-27 — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What PNC-27 moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
There is no established marker for this compound, and inventing one would be worse than saying so. A baseline CMP is the general precaution for anything experimental, not a targeted test.
What to do: Baseline liver and kidney function before, and again if you run it for any length of time.
This is genuinely experimental and the interference picture is unknown. Not 'probably fine' — unknown. There is no human interaction data, no established monitoring, and no way to predict combinations from a mechanism that is itself still being characterized. That is the honest position and it is the most useful thing on this page.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside PNC-27
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
PNC-27 — frequently asked questions
What is PNC-27?
PNC-27 (p53-derived anticancer research peptide) is a longevity & bioregulators research compound. Peptide combining a p53 HDM-2-binding domain with a membrane-resident domain — researched for selectively forming pores in cancer-cell membranes while sparing normal cells.
What dosing does the research reference for PNC-27?
In the research literature, PNC-27 is referenced in the 100-500mcg range, Research · Research. It is supplied as a lyophilized powder and reconstituted with bacteriostatic water; the calculator above converts a research amount into syringe units. For research use only — not a recommendation for human use.
What is the half-life of PNC-27?
PNC-27 has an approximate half-life of ~2-4 hrs, which is part of what determines how often it's dosed.
What's the evidence behind PNC-27?
Current evidence level: In-vitro + animal (oncology research). PNC-27 is offered for research purposes only and is not an approved medicine.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.